Literature DB >> 24099555

[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.

Anniina Koski1, Helena Ahtinen, Heidi Liljenback, Anne Roivainen, Anu Koskela, Minna Oksanen, Kaarina Partanen, Leena Laasonen, Kalevi Kairemo, Timo Joensuu, Akseli Hemminki.   

Abstract

Computed tomography (CT) is the most commonly used radiological response evaluation method in contemporary oncology. However, it may not be optimally suitable for assessment of oncolytic virus treatments because of paradoxical inflammatory tumor swellings, which result from virus treatments, particularly when viruses are armed with immunostimulatory molecules. Here we investigated the prognostic utility of CT and [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in oncolytic virus treatments. We also investigated possible appearance of false-positive FDG signals in FDG-PET imaging of humans and hamsters treated with oncolytic adenoviruses. First, immunocompetent Syrian hamsters were treated with intratumoral adenovirus injections, tumor growth was followed up, and [(18)F]-FDG-uptake was quantitated with small animal PET/CT. Second, we describe a retrospective patient series, essentially 17 individual case reports, of advanced cancer patients treated with oncolytic adenoviruses in the context of an Advanced Therapy Access Program (ATAP) who underwent radiological response evaluation with both contrast-enhanced CT and FDG-PET. Third, we collected a retrospective case series of radiological response and survival data of 182 patients treated with oncolytic adenoviruses in ATAP to evaluate the prognostic reliability of CT and FDG-PET. Overall, responses in CT and FDG-PET correlated well with each other and were equally reliable as prognostic markers for long survival after oncolytic adenovirus treatment. Interestingly, we observed that new FDG-avid lymph nodes appearing in FDG-PET after virus treatments may represent inflammatory responses and therefore should not be interpreted as treatment failure in the absence of other signs or verification of disease progression. We also observed indications that FDG-PET might be more sensitive in detection of responses than tumor size.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24099555     DOI: 10.1089/hum.2013.123

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

1.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

2.  Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.

Authors:  Anniina Koski; Simona Bramante; Anja Kipar; Minna Oksanen; Juuso Juhila; Lotta Vassilev; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-07-09       Impact factor: 11.454

3.  Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

Authors:  Simona Bramante; Anniina Koski; Ilkka Liikanen; Lotta Vassilev; Minna Oksanen; Mikko Siurala; Raita Heiskanen; Tiina Hakonen; Timo Joensuu; Anna Kanerva; Sari Pesonen; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2015-08-27       Impact factor: 8.110

4.  Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience.

Authors:  C Zamora; M Lopez; F Cunningham; F Collichio; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

5.  A century of oncolysis evolves into oncolytic immunotherapy.

Authors:  O Hemminki; A Hemminki
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

6.  Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

Authors:  Anna Kanerva; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Timo Joensuu; Otto Hemminki; Juni Palmgren; Kari Hemminki; Akseli Hemminki
Journal:  Mol Ther       Date:  2014-11-10       Impact factor: 11.454

7.  T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Aila Karioja-Kallio; Minna Oksanen; Riku Turkki; Nina Linder; Johan Lundin; Ari Ristimäki; Anna Kanerva; Anniina Koski; Timo Joensuu; Markus Vähä-Koskela; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-02-06       Impact factor: 11.454

8.  Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

Authors:  Kristian Taipale; Ilkka Liikanen; Anniina Koski; Raita Heiskanen; Anna Kanerva; Otto Hemminki; Minna Oksanen; Susanna Grönberg-Vähä-Koskela; Kari Hemminki; Timo Joensuu; Akseli Hemminki
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

9.  Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Authors:  Otto Hemminki; Suvi Parviainen; Juuso Juhila; Riku Turkki; Nina Linder; Johan Lundin; Matti Kankainen; Ari Ristimäki; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Dirk M Nettelbeck; Kalevi Kairemo; Kaarina Partanen; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncotarget       Date:  2015-02-28

10.  Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.

Authors:  Ilkka Liikanen; Anniina Koski; Maiju Merisalo-Soikkeli; Otto Hemminki; Minna Oksanen; Kalevi Kairemo; Timo Joensuu; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.